This is used for muscle spasm, strabismus, blepharospasm, achalasia, cervical dystonia, limb spasticity, overactive bladder, chronic migraine, severe primary axillary hyperhidrosis, and for cosmetic treatment of glabellar and lateral canthal lines.

Botulinum neurotoxin derived from Clostridium botulinum inhibits the release of acetylcholine (ACh) at the presynaptic nerve terminal, resulting in temporary relaxation of muscle contractions by blocking nerve signal transmission.

Botulinum Toxin Type A interrupts the communication between nerves and muscles. As a result, muscle stiffness gradually decreases, allowing improved muscle function and movement. This effect may help delay the need for surgical intervention and supports more natural growth and development, especially in children.

Glabellar lines: Inject 4 units (0.1 ml) into each of 5 sites, 2 in each corrugator muscle and 1 in procerus muscle for a total dose of 20 units

Canthal lines: Inject 4 units (0.1 ml) into 3 sites per side (6 total injection points) in the lateral orbicularis oculi muscle for a total of 24 units/0.6 ml (12 units per side)

Duration of activity is approximately 3-4 months. More frequent dosing not recommended.

Blepharospasm: 1.25- 2.5 units IM; not to exceed 200 units in 30 days.

Strabismus: 1.25- 5 units IM; <25 units per injection.

Chronic Migraine: Recommended total dose 155 units, as 0.1 ml (5 units) IM injections per each site divided across 7 head/neck muscles q12wk.

Overactive Bladder: Indicated for adults with overactive bladder symptoms (urge incontinence, urgency, frequency) who cannot use or do not adequately respond to anticholinergic medication.

100 units (divided into 20 intradetrusor injections of 5 units each) administered using cystoscopy.

No significant drug interactions have been identified, and there is limited documented evidence regarding interactions.

Similar to other immunoglobulin products, it should not be administered to individuals with a history of severe hypersensitivity to human immunoglobulin preparations. Patients with selective immunoglobulin A (IgA) deficiency may develop antibodies against IgA and are at risk of anaphylactic reactions when given blood products containing IgA.

No serious adverse reactions were reported in clinical studies. The most commonly observed reaction was skin rash. Other frequently reported effects include chills, muscle cramps, back pain, fever, nausea, vomiting, and wheezing, as noted in studies with similar human IVIG products.

Pregnancy Category C. Animal studies have indicated potential harmful effects on the fetus, and there are no adequate, well-controlled studies in humans. However, the potential benefits may justify its use in pregnant women despite possible risks.

Patients should be adequately hydrated before starting treatment. Renal function should be evaluated prior to therapy, including measurements of blood urea nitrogen (BUN) and serum creatinine. Continuous monitoring of renal function and urine output is especially important in patients at risk of acute renal failure. Elevations in BUN and serum creatinine have been reported within 1–2 days after administration of similar IVIG products. During treatment, vital signs should be closely monitored, and patients should be observed carefully for any adverse symptoms.

Drugs used in Cerebral Palsy, Vaccines, Anti-sera & Immunoglobulin